• Bertil Lindkvist
• Tore Robertsson
• Torsten Söderberg

The chairman of the board Eva Sjökvist Saers is convening the Nomination committee.

The Nomination committee shall submit proposals for decisions regarding the following subjects for the AGM on May 6, 2024:

a. Election of chairman at the AGM.
b. Determination of number of board members.
c. Determination of fees and other compensation for the board and its committees, divided between the chairman and other board members.
d. Determination of fees for auditors.
e. Election of board members and chairman of the board.
f. Election of auditors.
g. Principles for the Nomination committee's composition and work ahead of the 2025 AGM.

Shareholders who wish to submit proposals to the Nomination committee can do so via e-mail to: eva.sjokvist@saers.se

In order for the Nomination committee to be able to consider proposals, the proposal must have been received in good time before the AGM, but no later than December 22, 2023.

For further information, please contact:

Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 4,400 shareholders. For more information, please visit www.dicot.se.